CoChat
Sign Up
Cited by 67Pharmacology and Obesity TreatmentBlood Pressure and Hypertension StudiesBariatric Surgery and Outcomes

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

Derosa, G., Cicero, A. F. G., Murdolo, G., Piccinni, M. N., Fogari, E., Bertone, G., Ciccarelli, L., Fogari, R.·2005·Diabetes, Obesity and Metabolism
DOI 10.1111/j.1463-1326.2004.00372.x
Open this paper in CoChat — free account

Abstract

Aim: The aim of our study was to comparatively evaluate the efficacy and safety of orlistat and sibutramine treatment in obese hypertensive patients, with a specific attention to cardiovascular effects and to side effects because of this treatment. Methods: Patients were enrolled, evaluated and followed at three Italian Centres of Internal Medicine. We evaluated 115 obese and hypertensive patients. (55 males and 60 females; 26 males and 29 females, aged 50 ± 4 with orlistat; 28 males and 30 females, aged 51 ± 5 with sibutramine). All patients took antihypertensive therapy for at least 6 months before the study. We administered orlistat or sibutramine in a randomized, controlled, double‐blind clinical study. We evaluated anthropometric variables, blood pressure and heart rate (HR) during 12 months of this treatment. Results: A total of 113 completed the 4 weeks with controlled energy diet and were randomized to double‐blind treatment with orlistat (n = 55) or sibutramine (n = 58). Significant body mass index (BMI) improvement was present after 6 (p < 0.05), 9 (p < 0.02), and 12 (p < 0.01) months in both groups, and body weight (BW) improvement was obtained after 9 (p < 0.05) and 12 (p < 0.02) months in both groups. Significant waist circumference (WC), hip circumference (HC) and waist/hip ratio (W/H ratio) improvement was observed after 12 months (p < 0.05, respectively) in both groups. Significant systolic blood pressure (SBP) and diastolic blood pressure (DBP) improvement (p < 0.05) was present in orlistat group after 12 months. Lipid profile [total cholesterol (TC), low‐density lipoprotein‐cholesterol (LDL‐C) and triglycerides] reduction (p < 0.05, respectively) was observed in orlistat group and triglyceride reduction (p < 0.05) in sibutramine group after 12 months. No significant change was observed in sibutramine group during the study. No significant HR variation was obtained during the study in both groups. Of the 109 patients who completed the study, 48.1% of patients in the orlistat group and 17.5% of patients in the sibutramine group had side effects (p < 0.05 vs. orlistat group). Side‐effect profiles were different in the two treatment groups. All orlistat side effects were gastrointestinal events. Sibutramine caused an increase in blood pressure (both SBP and DBP) in two patients, but it has been controlled by antihypertensive treatment. The vitamin changes were small and all mean vitamin and β‐carotene values stayed within reference ranges. No patients required vitamin supplementation. Conclusions: Both orlistat and sibutramine are effective on anthropometric variables during the 12‐month treatment; in our sample, orlistat has been associated to a mild reduction in blood pressure, while sibutramine assumption has not be associated to any cardiovascular effect and was generically better tolerated than orlistat.

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2004.00372.x

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pharmacotherapy with orlistat and sibutramine have both been associated with weight loss, improvements in serum lipids, and insulin sensitivity.

    “Pharmacotherapy with the two currently approved drugs for obesity treatment, orlistat (a gastrointestinal lipase inhibitor) and sibutramine (a monoamine reuptake inhibitor), have both been associated with weight loss, improvements in serum lipids, and insulin sensitivity (76, 109, 270).”

    From Cardiac remodeling in obesity (2008) · cites this paper as [76]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Derosa, G., Cicero, A. F. G., Murdolo, G., Piccinni, M. N., Fogari, E., Bertone, G., Ciccarelli, L., & Fogari, R.
Affiliations
  • University of Pavia (IT)
  • University of Bologna (IT)
  • University of Perugia (IT)
Corresponding author
Derosa, G.
ORCID
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2004-11-10
Volume
7
Issue
1
Pages
47-55
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
DOI
10.1111/j.1463-1326.2004.00372.x
OpenAlex
W2166095598
Cited by
67
References
33
Citations by year
2024: 1 · 2023: 2 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 7 · 2016: 2 · 2015: 2 · 2014: 1 · 2013: 2 · 2012: 2
FWCI
3.13
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Diabetes Obesity and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
orlistat, sibutramine, obesity, hypertension, weight loss, blood pressure, cardiovascular safety, lipid profile, triglycerides, LDL cholesterol, heart rate, body mass index, waist circumference, waist-to-hip ratio, antihypertensive therapy, appetite suppressants, adverse effects, comparative efficacy and safety, antidiabetic drugs
MeSH terms
Orlistat, Analysis of Variance, Appetite Depressants, Blood Pressure, Cyclobutanes, Double-Blind Method, Female, Heart Rate, Humans, Hypertension, Lactones, Male, Middle Aged, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review